<DOC>
	<DOCNO>NCT00690560</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , vincristine , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Steroid therapy , prednisone , may effective treat cancer block body 's immune response . Monoclonal antibody , rituximab yttrium Y 90 ibritumomab tiuxetan , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving chemotherapy together prednisone monoclonal antibody therapy may kill cancer cell . PURPOSE : This phase II trial study well give doxorubicin together vincristine , cyclophosphamide , prednisone , rituximab follow rituximab yttrium Y 90 ibritumomab tiuxetan work treat patient newly diagnose large B-cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Rituximab , Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Newly Diagnosed Large B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine event-free survival patient large B-cell lymphoma treat CHOP-R follow consolidation therapy . Secondary - Determine overall survival . - Evaluate relapse-free survival patient achieve complete partial response . - Determine rate disease progression . - Determine response rate end study therapy . - Assess toxicity regimen . OUTLINE : This multicenter study . - Induction therapy : Patients receive CHOP-R regimen comprise doxorubicin hydrochloride IV , vincristine IV , cyclophosphamide IV , rituximab IV day 1 prednisone IV day 1-5 . Treatment repeat every 2 week 2 course . Patients achieve complete partial response , assess PET/CT scan , receive third course induction therapy . - Consolidation therapy : Patients receive rituximab IV day -8 0 yttrium Y 90 ibritumomab tiuxetan IV day 0 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm large Bcell lymphoma Stage I , II , III , IV disease Bone marrow lymph node involvement small cell lymphoma allow No serious , progressive pathology ( investigator 's discretion ) CD20positive disease Measurable disease No prior indolent lymphoma , treat No meningeal CNS lymphoma PATIENT CHARACTERISTICS : International prognostic index &lt; 2 ( adjust age ) Life expectancy &gt; 3 month ALT AST ≤ 2.5 time upper limit normal Bilirubin ≤ 30 mmol/L Creatinine ≤ 150 μmol/L HIV , hepatitis B virus , hepatitis C virus negative ( unless vaccine ) No contraindication chemotherapy immunotherapy No cancer past 5 year except basal cell skin cancer carcinoma situ cervix No contraindication venous catheter PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 30 day since prior concurrent investigational treatment No prior therapy No concurrent participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>